Oral and sublingual immunotherapy for food allergy

Anna Nowak-Wegrzyn, Sakura Sato, Alessandro Fiocchi, Motohiro Ebisawa

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: To critically appraise the recent most relevant studies in the rapidly advancing field of food oral and sublingual immunotherapy.

RECENT FINDINGS: Food allergen-specific immunotherapy via oral (OIT) and sublingual route (SLIT) increases the threshold of reactivity to peanut, cow's milk, egg, wheat, and many other foods in the majority of the treated individuals. This desensitized state is contingent upon the continued ingestion of the maintenance doses of the food. Permanent oral tolerance is achievable in a smaller subset of the treated individuals. The optimal duration of therapy has not been firmly established but is likely dependent on the phenotype (severity and persistence). Efficacy of food-OIT is superior compared with SLIT, whereas the safety of OIT is less favorable. Standardization of treatment protocols, maintenance dosing, duration of therapy, target populations and harmonization of the outcomes are top priorities at this stage.

SUMMARY: OIT and SLIT represent two different routes of food allergen-specific immunotherapy. Although significant progress has been made in the last decade, both treatment modalities are still in the very early stages of development and further investigations are necessary to optimize the protocols and improve safety while maximizing efficacy.

Original languageEnglish
JournalCurrent Opinion in Allergy and Clinical Immunology
DOIs
Publication statusE-pub ahead of print - Sep 12 2019

Fingerprint

Sublingual Immunotherapy
Food Hypersensitivity
Food
Immunologic Desensitization
Safety
Health Services Needs and Demand
Clinical Protocols
Triticum
Ovum
Milk
Therapeutics
Eating
Maintenance
Phenotype

Cite this

Oral and sublingual immunotherapy for food allergy. / Nowak-Wegrzyn, Anna; Sato, Sakura; Fiocchi, Alessandro; Ebisawa, Motohiro.

In: Current Opinion in Allergy and Clinical Immunology, 12.09.2019.

Research output: Contribution to journalArticle

@article{0f28342b0c3c4f588fe56b6459539549,
title = "Oral and sublingual immunotherapy for food allergy",
abstract = "PURPOSE OF REVIEW: To critically appraise the recent most relevant studies in the rapidly advancing field of food oral and sublingual immunotherapy.RECENT FINDINGS: Food allergen-specific immunotherapy via oral (OIT) and sublingual route (SLIT) increases the threshold of reactivity to peanut, cow's milk, egg, wheat, and many other foods in the majority of the treated individuals. This desensitized state is contingent upon the continued ingestion of the maintenance doses of the food. Permanent oral tolerance is achievable in a smaller subset of the treated individuals. The optimal duration of therapy has not been firmly established but is likely dependent on the phenotype (severity and persistence). Efficacy of food-OIT is superior compared with SLIT, whereas the safety of OIT is less favorable. Standardization of treatment protocols, maintenance dosing, duration of therapy, target populations and harmonization of the outcomes are top priorities at this stage.SUMMARY: OIT and SLIT represent two different routes of food allergen-specific immunotherapy. Although significant progress has been made in the last decade, both treatment modalities are still in the very early stages of development and further investigations are necessary to optimize the protocols and improve safety while maximizing efficacy.",
author = "Anna Nowak-Wegrzyn and Sakura Sato and Alessandro Fiocchi and Motohiro Ebisawa",
year = "2019",
month = "9",
day = "12",
doi = "10.1097/ACI.0000000000000587",
language = "English",
journal = "Current Opinion in Allergy and Clinical Immunology",
issn = "1528-4050",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Oral and sublingual immunotherapy for food allergy

AU - Nowak-Wegrzyn, Anna

AU - Sato, Sakura

AU - Fiocchi, Alessandro

AU - Ebisawa, Motohiro

PY - 2019/9/12

Y1 - 2019/9/12

N2 - PURPOSE OF REVIEW: To critically appraise the recent most relevant studies in the rapidly advancing field of food oral and sublingual immunotherapy.RECENT FINDINGS: Food allergen-specific immunotherapy via oral (OIT) and sublingual route (SLIT) increases the threshold of reactivity to peanut, cow's milk, egg, wheat, and many other foods in the majority of the treated individuals. This desensitized state is contingent upon the continued ingestion of the maintenance doses of the food. Permanent oral tolerance is achievable in a smaller subset of the treated individuals. The optimal duration of therapy has not been firmly established but is likely dependent on the phenotype (severity and persistence). Efficacy of food-OIT is superior compared with SLIT, whereas the safety of OIT is less favorable. Standardization of treatment protocols, maintenance dosing, duration of therapy, target populations and harmonization of the outcomes are top priorities at this stage.SUMMARY: OIT and SLIT represent two different routes of food allergen-specific immunotherapy. Although significant progress has been made in the last decade, both treatment modalities are still in the very early stages of development and further investigations are necessary to optimize the protocols and improve safety while maximizing efficacy.

AB - PURPOSE OF REVIEW: To critically appraise the recent most relevant studies in the rapidly advancing field of food oral and sublingual immunotherapy.RECENT FINDINGS: Food allergen-specific immunotherapy via oral (OIT) and sublingual route (SLIT) increases the threshold of reactivity to peanut, cow's milk, egg, wheat, and many other foods in the majority of the treated individuals. This desensitized state is contingent upon the continued ingestion of the maintenance doses of the food. Permanent oral tolerance is achievable in a smaller subset of the treated individuals. The optimal duration of therapy has not been firmly established but is likely dependent on the phenotype (severity and persistence). Efficacy of food-OIT is superior compared with SLIT, whereas the safety of OIT is less favorable. Standardization of treatment protocols, maintenance dosing, duration of therapy, target populations and harmonization of the outcomes are top priorities at this stage.SUMMARY: OIT and SLIT represent two different routes of food allergen-specific immunotherapy. Although significant progress has been made in the last decade, both treatment modalities are still in the very early stages of development and further investigations are necessary to optimize the protocols and improve safety while maximizing efficacy.

U2 - 10.1097/ACI.0000000000000587

DO - 10.1097/ACI.0000000000000587

M3 - Article

C2 - 31524655

JO - Current Opinion in Allergy and Clinical Immunology

JF - Current Opinion in Allergy and Clinical Immunology

SN - 1528-4050

ER -